To determine the effect of new oral anticoagulants (NOACs) on prescribing practices in older adults with atrial fibrillation (AF). DESIGN: Retrospective observational cohort study. SETTING: Academic medical center in St. Louis, Missouri. PARTICIPANTS: Individuals aged 75 and older with AF admitted to the hospital from October 2010 through September 2015 (N = 6,568, 50% female, 15% nonwhite). MEASUREMENTS: Information on NOACs and warfarin prescribed at discharge was obtained from hospital discharge summaries, and linear regression was used to examine quarterly trends in their use. Multivariable logistic regression was used to assess independent predictors of anticoagulant use. RESULTS: NOAC use increased over time (correlation coefficient (r) = 0.87, P < .001), warfarin use did not change (r = À0.16, P = .50), and overall anticoagulant use (NOACs and warfarin) increased (r = 0.68, P = .001). NOAC use increased over time in all age groups (75-79, 80-84, 85-89) except aged 90 and older, but increasing age attenuated the rate of NOAC uptake. There was no consistent relationship between age and warfarin or overall anticoagulant use, except that individuals aged 90 and older had consistently lower use. Overall, fewer than 45% of participants were prescribed an anticoagulant. In multivariable analysis, younger age, white race, female sex, higher hemoglobin, higher creatinine clearance, being on a medical service, hypertension, stroke or transient ischemic attack, no history of intracranial hemorrhage, and a modified HAS-BLED score of less than 3 increased the likelihood of receiving NOACs.
W
arfarin is effective for preventing stroke and systemic embolism in individuals with atrial fibrillation (AF), and before 2010, it was the only oral anticoagulant available in the United States for this purpose. Warfarin has many advantages, including low cost, relative ease of monitoring, and availability of reversal agents, but it also has several disadvantages, including slow onset of action, narrow therapeutic index requiring close monitoring, numerous food and drug interactions, and relatively high risk of major bleeding complications. 1, 2 In part for these reasons, warfarin is underused in a substantial proportion of individuals with AF, and older age is associated with progressively less warfarin use. 3, 4 Introduction of several new oral anticoagulants (NOACs) has addressed some of these disadvantages. As a group, NOACs have a rapid onset of action with morepredictable pharmacokinetics than warfarin and no need for routine monitoring. 2, 5 The NOACs are also at least as effective as warfarin for prevention of ischemic stroke and are associated with lower risk of intracranial hemorrhage, 6 an advantage of particular relevance to older adults. For these reasons, NOACs are now recommended as alternative first-line therapy for prevention of stroke and systemic emboli in nonvalvular AF. 7 Conversely, limitations to use of NOACs include higher cost, lack of readily accessible monitoring tests and reversal agents, and contraindications in individuals with severe kidney or liver disease. 2 Although several studies have examined trends in NOAC use in the general population, [8] [9] [10] [11] to our knowledge, no study has assessed NOAC use in older adults. The purpose of this study was therefore to examine changes in anticoagulation prescribing practices for older adults with AF since the introduction of NOACs in 2010, with particular attention to the associations between age, sex, race, comorbidities, and socioeconomic status with use of anticoagulation and trends in uptake of NOACs. We hypothesized that there would be a net increase in anticoagulant use over time, driven primarily by greater use of NOACs, and that age, kidney function, dementia diagnosis, and income but not sex or race would affect NOAC use.
METHODS

Study Population and Inclusion Criteria
This was a retrospective observational study. We included individuals aged 75 and older with AF admitted to BarnesJewish Hospital (a large tertiary-care academic medical center in St. Louis, MO) from October 2010 through September 2015 and discharged alive. Based on age alone, all participants had a CHA 2 DS 2 -VASc (congestive heart failure, hypertension, aged ≥75, diabetes mellitus, stoke or transient ischemic attack (TIA), vascular disease (peripheral vascular disease or coronary artery disease), aged 65-74, sex (female)) score 12 of at least two and were therefore candidates for anticoagulation. Seven thousand twelve individuals met the inclusion criteria; 444 with missing data on discharge medications were excluded, yielding 6,568 for the final analysis. For 2,029 individuals with multiple admissions, only the last available discharge record with medication data was retained for analysis. Individuals were grouped into calendar year quarters based on discharge date. The institutional review board at Washington University in St. Louis approved the study.
Data Collection
Individuals fulfilling the inclusion criteria were identified using a searchable electronic medical record database, the Clinical Investigation Data Exploration Repository (CIDER), maintained by the Washington University in St. Louis Center for Biomedical Informatics. Data were collected on demographic characteristics (age, sex, race), height, weight, selected laboratory tests (hemoglobin, creatinine) and service type (medical, surgical). Medical services included general medicine, neurology, and psychiatry. Surgical services included general surgery, cardiothoracic surgery, gynecology, neurosurgery, ophthalmology, orthopedic surgery, otolaryngology, plastic surgery, trauma surgery, and urology. Medical comorbidities were derived from International Classification of Diseases, Ninth Revision, codes and included heart failure, hypertension, diabetes mellitus, stroke, TIA, cerebrovascular disease, peripheral vascular disease, coronary artery disease, dementia, liver disease, bleeding, gastrointestinal bleeding, intracranial bleeding, lung or thoracic bleeding, soft tissue hematoma, alcohol abuse, and history of fall. Residential ZIP codes were used as a surrogate for economic status. Information on discharge medications including NOACs (dabigatran, rivaroxaban, apixaban), warfarin, aspirin, clopidogrel, prasugrel, and ticagrelor was obtained from hospital discharge summaries.
Other Variables
Creatinine clearance was calculated using the CockcroftGault equation. 13 Body mass index (BMI) was calculated as (height in meters)/(weight in kilograms). 2 A modified HAS-BLED score 14 was calculated that included hypertension, kidney disease, liver disease, stroke, bleeding history, elderly (aged ≥65), drugs (aspirin, clopidogrel, prasugrel, ticagrelor), and alcohol abuse but excluded labile international normalized ratio (INR) and nonsteroidal antiinflammatory drug (NSAID) use because data for these were not available. ZIP codes were used to obtain median income estimates from the U. 
Statistical Methods
Individual characteristics were summarized according to age category (75-79, 80-84, 85-89, ≥90) using means and standard deviations for continuous variables and frequency count (percent) for categorical variables. Continuous variables were compared using one-way analysis of variance. The chi-square or Fisher exact test was used to compare categorical variables. Nonnormal and ordinal variables were summarized according to the median (interquartile range) and compared using the Kruskal-Wallis test.
The linear trend in medications prescribed over time was examined using linear regression, with quarter of the year as the independent variable and percentage of patients taking medication as the dependent variable. For this analysis, quarter was treated as a continuous variable, with values ranging from 1 to 20 (first quarter October-December 2010; last available quarter July-September 2015). The Pearson correlation coefficient was calculated to describe strength of linear trend. To compare trends across subgroups, separate models were created that included the interaction between time and subgroup. The linear model assumptions of normal and homogeneous errors were evaluated by examining residual and normal probability plots. No significant deviations were noted.
A multivariable logistic regression model was built to examine independent predictors of NOAC and anticoagulant use. Variables were chosen a priori based on prior literature and clinical experience, including factors affecting risk of stroke, bleeding or likelihood of prescribing anticoagulation (age, race, sex, BMI, hemoglobin, creatinine clearance), or based on results from univariate analysis (P < .10, Supplementary Tables S1 and S2) and components of the CHA 2 DS 2 -VASc score. To adjust for time, a quarterly time variable was included and treated as a continuous variable. When conducting the multivariable analysis, missing data were imputed. Multiple data sets (5) were created, each using a sequential imputation algorithm (Appendix 1).
All statistical analyses were conducted in SAS version 9.4 (SAS Institute, Inc., Cary, NC). A two tailed P < .05 was considered statistically significant.
RESULTS
Baseline Characteristics
Baseline characteristics of the cohort stratified according to age group are summarized in Table 1 . Of 6,568 participants, 36% were aged 75 to 79, 31% aged 80 to 84, 22% aged 85 to 89, and 11% aged 90 and older. Half of the cohort was female, and 85% of participants with available race data were white. The percentage of women increased with increasing age (P < .001). The average median income of the cohort was $52,306. The median CHADS 2 (congestive heart failure, hypertension, aged ≥75, diabetes mellitus, stroke/TIA) 15 score was 3 and the median CHA 2 DS 2 -VASc 12 score was 4. The prevalence of comorbidities varied according to age group (Table 1) . Baseline characteristics of the cohort stratified according to anticoagulation use are shown in Supplementary Table S3 .
Quarterly Trends in Use of Anticoagulation
Quarterly trends in NOAC, warfarin, and overall anticoagulant use are summarized in Figure 1A -C. NOAC use increased significantly over time (correlation coefficient (r) 0.87, P < .001). There was no significant change in warfarin use over time (r = À0.16, P = .50). Overall anticoagulant use increased over time (r = 0.68, P = .001) but remained less than 45% throughout the study period.
Quarterly Trends in Use of Anticoagulants According to Age Group
Quarterly trends in NOAC, warfarin, and anticoagulant use according to age group are summarized in Figure 2A -C. Although use of NOACs increased significantly over time for all age groups except aged 90 and older, increasing age attenuated the rate of use (P for interaction = .007). Use of warfarin increased only in participants aged 85 to 89 (remaining unchanged in the other age groups), and overall use of anticoagulants increased only in participants aged 75 to 79 and 85 to 89 (remaining unchanged in the other age groups). Overall, there was no consistent association between age and prescription of warfarin or any anticoagulant, except that participants aged 90 and older had consistently lower use. There were significant differences in trends of warfarin (P for interaction = 0.03) and anticoagulant (P for interaction <.001) use over time between age groups.
Quarterly Trends in Use of NOACs for Other Subgroups
Quarterly trends according to sex, race, renal function, dementia diagnosis, and income are summarized in Supplementary Figures S1 through S5. NOAC use increased over time in women and men, whites and nonwhites, participants without dementia (no change in individuals with dementia), individuals in all renal function categories (except Stage V chronic kidney disease), and individuals in all tertiles of median income. There were no significant differences in rate of NOAC uptake between men and women (P for interaction = .93), whites and nonwhites (P = .51), individuals with and without dementia diagnosis (P = .05), or according to income tertile (P = .70). Poorer renal function was associated with lower NOAC use over time (P < .001).
Factors Predictive of NOAC Use
Factors independently predictive of NOAC use are summarized in Table 2 . In the multivariable model that included age, sex, race, median income, BMI, hemoglobin, creatinine clearance, service type, heart failure, hypertension, diabetes mellitus, stroke or TIA, peripheral vascular disease, coronary artery disease, dementia, gastrointestinal bleeding, intracranial bleeding, modified HAS-BLED score, and time, 11 factors independently affected the likelihood of NOAC use. These included age ((vs 75-79: 80-85 age, odds ratio (OR) = 0.67, P = .001; 85-89, OR = 0.665, P = .003; ≥90, OR = 0.390, P < .001), female sex (OR = 1.33, P = .005), white race (OR = 1.50, P = .02), hemoglobin (per 1-g/dL increase, OR = 1.20, P < .001), creatinine clearance (≥50 vs <50 mL/min, OR = 1.37, P = .01), medical service (vs surgical service: OR = 1.26, P = .04), hypertension (OR = 1.32, P = .04), stroke or TIA (OR = 1.57, P = .02), history of intracranial bleeding (OR = 0.39, P = .04), HAS-BLED score ≥3 (OR = 0.74, P = .01), and time from start of the analysis (per 1-quarter increase: OR = 1.08, P < .001).
Factors Predictive of Anticoagulant Use
Factors independently predictive of anticoagulant use are summarized in Supplementary Table S4. In the multivariable model, 15 factors independently affected likelihood of anticoagulant use. These included age (vs 75-79, ≥90: OR = 0.55, P < .001), white race (OR = 1.49, P < .001), median income (1st tertile vs. 3rd tertile OR = 1.18, P = .02), BMI (vs <25.0 kg/m 2 , 25.0-29.9: OR = 1.27, P < .001; ≥30.0: OR = 1.41, P < .001), hemoglobin (per 1-g/dL increase: OR = 1.13, P < .001), medical service (vs surgical service: OR = 1.32, P < .001), heart failure (OR = 1.15, P < .001), cerebrovascular disease (OR = 0.52, P = .02), dementia (OR = 0.51, P < .001), liver disease (OR = 0.57, P = .001), gastrointestinal bleeding (OR = 0.63, P = .009), intracranial bleeding (OR = 0.26, P < .001), history of falls (OR = 0.60, P < .001), modified HAS-BLED score ≥3 (OR = 0.811, P = .003), and time from start of the analysis (per 1 quarter increase: OR = 1.02, P < .001).
DISCUSSION
Over 5 years, NOAC use in older adults with AF admitted to a tertiary academic medical center increased progressively, whereas warfarin use remained stable, resulting in an overall increase in prescription of anticoagulants. The overall trend was generally consistent across demographic subgroups defined according to age, sex, and race, but the rate of NOAC uptake declined significantly with increasing age.
Prior studies have assessed the effect of the introduction of NOACs on AF treatment patterns in various populations, but no study has assessed treatment patterns specifically in older adults. One study of individuals newly (24) 283 (20) 93 (12) Hemoglobin, g/dL, mean Creatinine clearance, n (%) <15.0
(3)
47 (2) 44 (2) 47 (4) 31 ( 613 (30) 424 (29) 149 (20) <.001
Stroke, transient ischemic attack, n (%)
391 (6) 104 (4) 130 (6) 98 (7) 59 (8) <.001
Cerebrovascular disease, n (%)
91 (1) 22 (1) 36 (2) 26 (2) 7
.03
Peripheral vascular disease, n (%) 1,077 (16) 399 (17) 316 (16) 237 (16) 125 (17) .66
Coronary artery disease, n (%) .20
Dementia, n (%)
769 (12) 152 (6) 217 (11) 235 (16) 165 (22) <.001
Liver disease, n (%)
213 (3) 100 (4) 59 (3) 42 (3) 12 (2) .001
Gastrointestinal bleeding, n (%)
199 (3) 72 (3) 65 (3) 43 (3) 19 (3) .84
Intracranial bleeding, n (%)
157 (2) 40 (2) 56 (3) 45 (3) 16 (2) .02
History of fall, n (%)
350 (5) 77 (3) 88 (4) 111 (8) 74 (10) <.001 (63) 938 (65) 509 (68) .04
All percentages indicate the proportion of participants with available data. diagnosed with AF with a mean age of 69 evaluated over a similar period of time (2010) (2011) (2012) (2013) (2014) (2015) found an increase in anticoagulation therapy driven primarily by prescription of NOACs. 16 Another study in individuals with AF hospitalized with TIA or stroke conducted in the first 2 years after the introduction of NOACs showed no change in anticoagulant use but a trend toward switching from warfarin to NOACs. 17 The increase in use of NOACs observed in these studies, including ours, reflects greater familiarity with NOACs and better understanding among physicians of indications for their use. We anticipate that this trend will continue, especially as prices of these drugs decline and with approval of novel reversal agents.
An important finding of our study is that NOAC use increased over time in all age groups except individuals aged 90 and older, and the rate of new use declined with age. Warfarin use increased only in individuals 85 to 89 and overall use of anticoagulants increased only in individuals 75 to 79 and 85 to 89, most likely representing a chance finding, and there were no clear trends in use over time as a function of age, except that participants aged 90 and older were less likely to receive treatment.
Although age is a potent risk factor for stroke and systemic embolization in individuals with AF, anticoagulation is underused in older adults. 3, 4 Even with the availability of NOACs, overall use of anticoagulation was less than 45% throughout the study period. Factors associated with low usage rates in our population include nonwhite race, low income, low BMI, low hemoglobin, being on a surgical service, not having heart failure, cerebrovascular disease, dementia, liver disease, gastrointestinal bleeding, intracranial bleeding, history of falls, and a modified HAS-BLED score of 3 or greater. For warfarin, it is likely that drug and dietary interactions and requirement for close monitoring with frequent blood tests also contributed to low usage rates. Our results suggest that these and other concerns are especially pronounced in individuals aged 90 and older. Alternatively, NOACs may have abated these concerns to a greater extent in individuals aged 75 to 79 than in those aged 90 and older. Nevertheless, our data indicate that there is considerable opportunity to improve use of anticoagulation in older adults with AF.
As anticipated, there were no differences in the rate of NOAC use between women and men or between whites and nonwhites (nonsignificant p-values for time interaction), although sex and race were found to be predictors of NOAC prescription after adjusting for time and other factors. Women were more likely to be prescribed a NOAC than men (OR = 1.33, P = .005) and whites were more likely to be prescribed a NOAC than nonwhites (OR = 1.50, P = .02); In other words, although rate of NOAC use did not differ according to sex or race, overall use was higher in women and whites than in men and nonwhites ( Supplementary Figures S1 and S2) .
Also as expected, there was a difference in NOAC use based on renal function, such that participants with higher creatinine clearance were more likely to be prescribed NOACs. In bivariate analysis, NOAC use increased over time in participants without dementia but not in those with dementia, although the difference was not significant (P = .05). After adjusting for time and other factors, dementia diagnosis did not affect the likelihood of being prescribed a NOAC but was associated with lower overall anticoagulant use. Other studies have also shown lower use of anticoagulation in individuals with cognitive impairment. 18, 19 This may be due to a perception of potentially lower net benefit of anticoagulation in this group, such that the benefit may no longer outweigh the greater risk of bleeding and other side effects, although a recent study showing that discontinuation of warfarin after a diagnosis of dementia is associated with greater risk of stroke and death has challenged this view. 20 Having a history of falling was also associated with lower use of anticoagulation overall but not with use of NOACs. This may be because of the associated lower risk of intracranial hemorrhage with NOACs. 6 NOAC use increased over time in all tertiles of income, but contrary to expectations, there was no difference in the rate of use according to income tertile after adjusting for time and other variables. Given the higher cost of NOACs, we had expected higher use in individuals with higher incomes.
Limitations of Study
Our study has several limitations. It is based on data from a single center and may not be representative of other populations. The retrospective design and use of hospital records may be associated with coding errors and other inaccuracies in the data. Specifically, it is likely that geriatric syndromes such as falls and cognitive impairment are undercoded. Other factors not included in our analysis such as education level and marital status may have affected prescription of warfarin and NOACs; in particular, we did not have information on reasons for nonprescription of anticoagulants in individuals, which may include physician and patient factors. We used ZIP code as a surrogate for income, but this may not accurately reflect an individual's socioeconomic status, although all participants were potentially eligible for Medicare, which may reduce disparities in ability to pay for medications.
CONCLUSION
In individuals aged 75 and older admitted to a large academic hospital, the introduction of NOACs was associated with an increase in the use of oral anticoagulation for AF. Nonetheless, despite high risk of stroke based on CHA 2 DS 2 -VASc score, fewer than 45% of participants were discharged on an anticoagulant. Additional research is needed to optimize prescribing practices for older adults with AF, including a better understanding of the reasons for not using anticoagulants in a high proportion of people. Author Contributions: RBF: Design, data collection, interpretation of data, drafting and revision of manuscript. EN: Analysis, interpretation of data, revision of the manuscript. MWR: Conception, design, interpretation of data, revision of manuscript.
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